Union Pharm (600513.SH): The application for the listing of the chemical raw material drug Agomelatine has been approved.

Intelligence Finance and Economics APP News, Lianhuan Pharmaceutical (600513.SH) announced that the company recently received the "Notice of Approval for the Market Application of Chemical Raw Materials for Agatroban" issued by the State Drug Administration. Agatroban is a direct thrombin inhibitor that reversibly binds to the active site of thrombin. Its injection is suitable for: (1) improvement of neurological symptoms (paralysis) and daily activities (walking, standing, sitting, eating) of patients in the acute phase of ischemic stroke within 48 hours of onset; (2) improvement of ulcers, rest pain, and cold sensations in patients with chronic arterial occlusive disease (thrombotic occlusive arteritis, occlusive arteriosclerosis).